Decitabine/Depsipeptide Infusion in Patients with Pulmonary and Pleural Malignancies
Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion
in Patients with Pulmonary and Pleural Malignancies
Background:
Preliminary research indicates that the drug decitabine (DAC) enhances the immune
response to tumors and may enable the p16 gene, called the 'suppressor gene,'
to function normally. The drug depsipeptide (DP) appears to help kill cancer cells
and prevent the growth of new cancer cells. These two drugs have been administered
separately in the past. This study will examine the effect of the two drugs when
they are given together
Location and Contact Information:
Maryland
National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, 20892,
United States;
Recruiting
Tricia Kunst, R.N. 3014024399 kunstt@mail.nih.gov
